trending Market Intelligence /marketintelligence/en/news-insights/trending/sbl2b_f7rc8doak58mb_g2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Galectin Therapeutics closes private placements

Shareholder Advocates Say New SEC Policy To Prompt Litigation, Less Transparency

Groups Urge Business Roundtable CEOs To Act On New Corporate Purpose Declaration

State of South Korean OTT Video: Subscription

Global Streaming Media Device Sales Forecast To Flatten In 5 Year Outlook


Galectin Therapeutics closes private placements

Galectin Therapeutics Inc. raised $3 million in a private placement of its common stock.

The company separately closed on an additional sale of its series B-3 preferred stock, resulting in about $1 million of additional proceeds.

In the placement of common stock, one existing investor and a new investor purchased 2,814,230 common shares and received warrants for common stock exercisable at $5.00 per share.

Under a Sept. 22 stock purchase agreement, 10X Fund LP purchased 1,008,000 series B-3 preferred shares, which are convertible into 896,997 common shares, for a purchase price of about $1 million. The fund also received warrants for common stock exercisable at $3.00 per share.

Peter Traber, president, CEO and chief medical officer, said in a statement that proceeds from the private placement will provide funding for the company's clinical programs, particularly a clinical trial that will assess the efficacy of Galectin's lead compound GR-MD-02 in patients with NASH cirrhosis, liver inflammation and damage caused by a buildup of fat in the liver.